Glia: A novel drug discovery target for clinical pain

Nature Reviews Drug Discovery

Volumn 2, Issue 12, 2003, Pages 973-985

  Watkins, Linda R ^a   Maier, Steven F ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DIZOCILPINE; ETANERCEPT; FLUOROCITRIC ACID; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; KRONOS; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUTRALIZING ANTIBODY; NPC 037282; PROPENTOFYLLINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 10; SCIO 323; SCIO 469; SD 282; SEMAPIMOD; TERIFLUNOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIA; BIRTH DEFECT; BLOOD BRAIN BARRIER; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG TARGETING; GLIA CELL; HEAT; HUMAN; HYPERALGESIA; NERVE CELL; NEUROMODULATION; NEUROTOXICITY; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TARGET CELL; TOUCH; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0347169249     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1251     Document Type: Review

References (134)

1. McQuay, H., Carroll, D., Jadad, A. R., Wiffen, P. & Moore, A. Anticonvulsant drugs for management of pain: a systematic review. Brit. Med. J. 311, 1047-1052 (1995).
2. McQuay, H. J. et al. A systematic review of antidepressants in neuropathic pain. Pain 68, 217-227 (1996).
3. Watkins, L. R. & Maier, S. F. Beyond neurons: Evidence that immune and glial cells contribute to pathological pain states. Physiol. Rev. 82, 981-1011 (2002).
4. Woolf, C. J. & Salter, M. W. Neuronal plasticity: increasing the gain in pain. Science 288, 1765-1769 (2000).
5. Pekny, M. in Progress in Brain Research: Glial Cell Funtion (eds Castellano-Lopez, B. & Nieto-Sampedro, M.) 23-30 (Elsevier, Amsterdam, 2001).
6. Benveniste, E. N. in Neuroglia (eds Kettenmann, H. & Ransom, B. R.) 700-716 (Oxford, New York, 1995).
7. Perry, V. H. Macrophages and the Nervous System (Landes, Austin, 1994).
8. Gehrmann, J. & Kreutzberg, G. W. in Neuroglia (eds Kettenmann, H. & Ransom, B. R.) 883-904 (Oxford, New York, 1995).
9. Araque, A., Parbura, V., Sanzgiri, R. P. & Hayden, P. G. Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 22, 208-215 (1999).
10. Garrison, C. J., Dougherty, P. M., Kajander, K. C. & Carlton, S. M. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res. 565, 1-7 (1991).
11. Garrison, C. J., Dougherty, P. M. & Carlton, S. M. GFAP expression in lumbar spinal cord of naive and neuropathic rats treated with MK-801. Exp. Neurol. 129, 237-243 (1994).
12. Watkins, L. R., Milligan, E. D. & Maier, S. F. Glial activation: a driving force for pathological pain. Trends Neurosci. 24, 450-455 (2001).
13. Berg-Johnsen, J., Paulsen, R. E., Fonnum, F. & Langmoen, I. A. Changes in evoked potentials and amino acid content during fluorocitrate action studied in rat hippocampal cortex. Exp. Brain Res. 96, 241-246 (1993).
14. Hassel, B., Paulsen, R. E., Johnson, A. & Fonnum, F. Selective inhibition of glial cell metabolism by fluorocitrate. Brain Res. 249, 120-124 (1992).
15. Tikka, T. M. & Koistinaho, J. E. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J. Immunol. 166, 7527-7533 (2001).
16. Meller S. T., Dykstra, C., Grzbycki, D., Murphy, S. & Gebhart, G. F. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 33, 1471-1478 (1994).
17. Watkins, L. R., Martin, D., Ulrich, P., Tracey, K. J. & Maier, S. F. Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain 71, 225-235 (1997).
18. Milligan, E. D. et al. Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120. Brain Res. 861, 105-116 (2000).
19. Milligan, E. D. et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain. J. Neurosci. 23, 1026-1040 (2003).
20. Raghavendra, V., Tanga, F. & DeLeo, J. A. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 306, 624-630 (2003).
21. Ledeboer, A. et al. Selective inhibition of spinal cord microglial activation attenuates mechanical allodynia in rat models of pathological pain. Proc. Soc. Neurosci. (in the press).
22. Cholewinski, A. J., Hanley, M. R. & Wilkin, G. P. A phosphoinositide-linked peptide response in astrocytes: evidence for regional heterogeneity. Neurochem. Res. 13, 389-394 (1988).
23. Beaujouan, J. O. et al. Marked regional heterogeneity of 125I-Bolton Hunter substance P binding and substance P-induced activation of phospholipase C in astrocyte cultures from the embryonic or newborn rat. J. Neurochem. 54, 669-675 (1990).
24. Sung, B., Lim, G. & Mao, J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J. Neurosci. 23, 2899-2910 (2003).
25. Ochalski, P. A., Frankenstein, U. N., Hertzberg, E. L. & Nagy, J. I. Connexin-43 in rat spinal cord: localization in astrocytes and identification of heterotypic astro-oligodendrocytic gap junctions. Neurosci. 76, 931-945 (1997).
26. Li, W. E. & Nagy, I. Activation of fibres in rat sciatic nerve alters phosphorylation state of connexin-43 at astrocytic gap junctions in spinal cord: evidence for junction regulation by neuronal-glial interactions. Neurosci. 97, 113-123 (2000).
27. Palma, C. et al. Functional characterization of substance P receptors on cultured human spinal cord astrocytes: synergism of substance P with cytokines in inducing interleukin-6 and prostaglandin E2 production. Glia 21, 183-193 (1997).
28. Tikka, T., Fiebich, B. L., Goldsteins, G., Keinanen, R. & Koistinaho, J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 21, 2580-2588 (2001).
29. Bartlett, P. F. Pluripotential hemopoietic stem cells in adult mouse brain. Proc. Natl Acad. Sci. USA 79, 2722-2725 (1982).
30. Carson, M. J., Reilly, C. R., Sutcliffe, J. G. & Lo, D. Mature microglia resemble immature antigen-presenting cells. Glia 22, 72-85 (1998).
31. Fedoroff, S. in Neuroglia (eds Kettenmann, H. & Ransom, B. R.) 162-184 (Oxford, New York, 1995).
32. Lee, J. C., Mayer-Proschel, M. & Rao, M. S. Gliogenesis in the central nervous system. Glia 30, 105-121 (2000).
33. Watkins, L. R., Hansen, M. K., Nguyen, K. T., Lee, J. E. & Maier, S. F. Dynamic regulation of the proinflammatory cytokine, interleukin-1β: molecular biology for non-molecular biologists. Life Sci. 65, 449-481 (1999).
34. Milligan, E. D. et al. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J. Neurosci. 21, 2808-2819 (2001).
35. Harrison, J. K. et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl Acad. Sci. USA 95, 10896-10901 (1998).
36. Watkins, L. R., Milligan, E. D. & Maier, S. F. in Advances in Pain Research and Therapy lees Dostrovsky, J. O., Carr, D. B. & Koltzenberg, M.) 369-385 (IASP, Seattle, 2003).
37. Verge, G. et al. Mapping fractalkine and its receptor (CX3CR1) in a rat model of sciatic inflammatory neuropathy (SIN). Proc. Soc. Neurosci. 28, 455.3 (2002).
38. Chapman, G. A. et al. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J. Neurosci. 20, RC87 (1-5) (2000).
39. Dinarello, C. A. in Cytokines and Pain (eds Watkins, L. R. & Maier, S. F.) 1-19 Birkhauser, Basel, 1999).
40. Maier, S. F. & Watkins, L. R. Cytokines for psychologists: implications of bi-directional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol. Rev. 105, 83-107 (1998).
41. DeLeo, J. A., Colburn, R. W., Nochols, M. & Malhotra, A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J. Interferon Cytokine Res. 16, 695-700 (1996).
42. Falchi, M., Ferrara, G., Gharib, C. & Dib, B. Hyperalgesic effect of intrathecally administered interleukin-1 in rats. Drugs Exp. Clin. Res. 27, 97-101 (2001).
43. Reeve, A. J., Patel, S., Fox, A., Walker, K. & Urban, L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur. J. Pain 4, 247-257 (2000).
44. Tadano, T. et al. Induction of nociceptive responses by intrathecal injection of interleukin-1 in mice. Life Sci. 65, 255-261 (1999).
45. Oka, T. & Hori, T. in Cytokines and Pain (eds Watkins, L. R. & Maier, S. F.) 183-204 (Birkhauser, Basel, 1999).
46. Sweitzer, S. M., Martin, D. & DeLeo, J. A. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neurosci. 103, 529-539 (2001).
47. Clark, A. R., Dean, J. L. E. & Saklatvala, J. Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett. 546, 37-44 (2003).
48. Svensson, C. I. et al. Activation of p38 MAP kinase in spinal microglia is a critical link in inflammation induced spinal pain processing. J. Neurochem. (in the press).
49. 2 release and thermal hyperalgesia. Neuroreport 14, 1153-1157 (2003).
50. Schafers, M., Svensson, C. I., Sommer, C. & Sorkin, L. S. Tumor necrosis factor induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J. Neurosci. 23, 2517-2521 (2003).
51. Jones, T. L. et al. Involvement of p38α MAPK in capsaicin-induced hyperalgesia. Proc. Soc. Neurosci. 28, 56.5 (2002).
52. Milligan, E. D. et al. Systemic administration of CNI-1493, a p38 MAP kinase inhibitor, blocks HIV-1 gp120-induced enhanced pain states in rats. J. Pain 2, 326-333 (2001).
53. Sweitzer, S. M., Schubert, P. & DeLeo, J. A. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J. Pharmacol. Exp. Ther. 297, 1210-1217 (2001).
54. Winkelstein, B. A., Rutkowski, M. D., Sweitzer, S. M., Pahl, J. L. & DeLeo, J. A. Nerve injury proximal or distal to the DRG induces similar spinal glial activation and selective cytokine expression but differential behavioral responses to pharmacologic treatment. J. Comp. Neurol. 2, 127-139 (2001).
55. Hashizume, H., Rutkowski, M. D., Weinstein, J. N. & DeLeo, J. A. Central administration of methotrexate reduces mechanical allodynia in an animal model of radiculopathy/sciatica. Pain 87, 159-169 (2000).
56. Sommer, C., Marziniak, M. & Myers, R. R. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain 74, 83-91 (1998).
57. George, A., Marziniak, M., Schafers, M., Toyka, K. V. & Sommer, C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-α, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 88, 267-275 (2000).
58. Eriksson, T., Bjorkman, S. & Hoglund, P. Clinical pharmacology of thalidomide. Eur. J. Clin. Pharmacol. 5, 365-376 (2001).
59. Clemmensen, O. J., Olsen, P. Z. & Andersen, K. E. Thalidomide neurotoxicity. Arch. Dermatol. 120, 338-341 (1984).
60. Strle, K. et al. Interleukin-10 in the brain. Crit. Rev. Immunol. 21, 427-449 (2001).
61. Moore, K. W., deWaal Malefyt, R., Coffman, R. L. & O'Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683-765 (2001).
62. Ledeboer, A. et al. Regional and temporal expression patterns of interleukin-10, interleukin-10 receptor and adhesion molecules in the rat spinal cord during chronic relapsing EAE. J. Neuroimmunol. 136, 94-103 (2003)
63. Yu, C.-G., Fairbanks, C. A., Wilcox, G. L. & Yezierski, R. P. Effects of agmatine, interleukin-10 and cyclosporin on spontaneous pain behavior following excitotoxic spinal cord injury in rats. J. Pain (in the press).
64. Laughlin, T. M., Bethea, J. R., Yezierski, R. P. & Wilcox, G. L. Cytokine involvement in dynorphin-induced allodynia. Pain 84, 159-167 (2000).
65. Plunkett, J. A., Yu, C.-G., Easton, J. M., Bethea, J. R. & Yezierski, R. P. Effects of interelukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. Exper. Neurol. 168, 144-154 (2001).
66. Hornfeldt, C. S. & Larson, A. A. Seizures induced by fluoroacetic acid and fluorocitric acid may involve chelation of divalent cations in the spinal cord. Eur. J. Pharmacol. 179, 307-313 (1990).
67. Yrjanheikki, J., Keinanen, R., Pellikka, M., Hokfelt, T. & Korstinaho, J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Neurobiology 95, 15769-15774 (1998).
68. Lin, S. et al. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition of p38 MAP kinase in rat cerebellar granule neurons. Neurosci. Lett. 315, 61-64 (2001).
69. Kary, S. & Burmester, G. R. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int. J. Clin. Pract. 57 (2003).
70. Calabrese, L. H. Molecular differences in anticytokine therapies. Clin. Exp. Rheumatol. 21, 241-248 (2003).
71. Mielke, R. et al. Propentofylline in the treatment of vascular dementia and Alzheimer type dementia: overview of phase I and phase II clinical trials. Alzheimer Dis. Assoc. Disord. 12, S29-35 (1998).
72. Rother, M. et al. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Dement. Geriatr. Cogn. Disord. 9, 36-43 (1998).
73. Plaschke, K. et al. Neuromodulatory effect of propentofylline on rat brain under acute and long-term hypoperfusion. Br. J. Pharmacol. 133, 107-116 (2001).
74. Wu, Y. P., McRae, A., Rudolphi, K. & Ling, E. A. Propentofylline attenuates microglial reaction in the rat spinal cord induced by middle cerebral artery occlusion. Neurosci. Lett. 260, 17-20 (1999).
75. Numagami, Y., Marro, P. J., Mishra, O. P. & Delivoria-Papadopoulos, M. Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet. Neuroscience 84, 1127-1133 (1998).
76. Schubert, P. et al. Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann. NY Acad. Sci. 903, 24-33 (2000).
77. Schubert, P., Ogata, T., Marchini, C., Ferroni, S. & Rudolphi, K. Protective mechanisms of adenosine in neurons and glial cells. Ann. NY Acad. Sci. 825, 1-10 (1997).
78. Sawynok, J. & Liu, X. J. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog. Neurobiol. 69, 313-340 (2003).
79. Si, Q., Nakamura, Y., Ogata, T., Kataoka, K. & Schubert, P. Differential regulation of microgial activation by propentofylline via cAMP signaling. Brain Res. 812, 97-104 (1998).
80. Matthews, S. J. & McCoy, C. Thalidomide: a review of approved and investigational uses. Clin. Ther. 25, 342-395 (2003).
81. Mujagic, H., Chabner, B. A. & Mujagic, Z. Mechanisms of action and potential therapeutic uses of thalidomide. Croat. Med. J. 43, 274-285 (2002).
82. 2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J. Immunol. 168, 2644-2651 (2002).
83. Gallilly, R., Kipper-Galperin, M. & Brenner, T. Mycoplasma fermentans-induced inflammatory response of astrocytes: selective modulation by aminoguanidine, thalidomide, pentoxifylline and IL-10. Inflammation 23, 495-505 (1999).
84. Peterson, P. K. et al. Thalidomide inhibits tumor necrosis factor-α production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J. Infect. Dis. 172, 1137-1140 (1995).
85. Moreira, A. L. et al. Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J. Exp. Med. 177, 1675-1680 (1993).
86. Corral, L. G. et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. 163, 380-386 (1999).
87. Li, J., Luo, S., Hong, W., Zhou, Z. & Zou, W. Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients. Zhonghua Zhong Liu Za Zhi 24, 254-256 (2002).
88. Bauditz, J., Wedel, S. & Lochs, H. Thalidomide reduces tumour necrosis factor-α and interleukin-12 production in patients with chronic active Crohn's disease. Gut 50, 196-200 (2002).
89. Jin, S. H., Kim, T. I., Han, D. S., Shin, S. K. & Kim, W. H. Thalidomide suppresses the interleukin 1β-induced NF-κB signaling pathway in colon cancer cells. Ann. NY Acad. Sci. 973, 414-418 (2002).
90. Thiele, A. et al. Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide. Eur. J. Pharmacol. 453, 325-334 (2002).
91. Rajkumar, S. V., Fonseca, R. & Witzig, T. E. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch. Intern. Med. 161, 2502-2503 (2001).
92. Prager, J., Fleischman, J. & Lingua, G. Open label clinical experience of thalidomide in the treatment of complex regional pain syndrome Type 1. J. Pain 4, S68 (2003).
93. Sanders, S. & Harisdangkul, V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am. J. Med. Sci. 323, 190-193 (2002).
94. Furst, D. E. Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Baillieres Clin. Rheumatol. 9, 711-729 (1995).
95. Kraan, M. C. et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. 43, 1820-1830 (2000).
96. Elkayam, O. et al. Active leflunomide metabolite inhibits interleukin-1β, tumour necrosis factor-α, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann. Rheum. Dis. 62, 440-443 (2003).
97. Cutolo, M. et al. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann. Rheum. Dis. 62, 297-302 (2003).
98. Manna, S. K., Mukhopadhyay, A. & Aggarwal, B. B. Leflunomide suppresses TNF-induced cellular responses: effects on NF-κB, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J. Immunol. 165, 5962-5969 (2000).
99. Fox, R. I. et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol. 93, 198-208 (1999).
100. Herrmann, M. L., Schleyerbach, R. & Kirschbaum, B. J. Leflunomide: an immunomodulatoy drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 47, 273-289 (2000).
101. Miljkovic, D. et al. Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes. Brain Res. 889, 331-338 (2001).
102. Bao, L. et al. Adjuvant-induced arthritis: IL-1β, IL-6 and TNF-α are up-regulated in the spinal cord. Neuroreport 12, 3905-3908 (2001).
103. Bruce-Gregorios, J. H., Soucy, D. M., Chen, M. G. & Norenberg, M. D. Effect of methotrexate on glial fibrillary acidic protein content of astrocytes in primary culture. J. Neuropathol. Exp. Neurol. 50, 118-125 (1991).
104. el-Badawi, M. G., Fatani, J. A., Bahakim, H. & Abdalla, M. A. Light and electron microscopic observations on the cerebellum of guinea pigs following low-dose methotrexate. Exp. Mol. Pathol. 53, 211-222 (1990).
105. Dongo-Sorbello, G. S. & Bertino, J. R. Current understanding of metrotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 86, 121-127 (2001).
106. Chan, E. S. & Cronstein, B. N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 4, 266-273 (2002).
107. Cronstein, B. N., Naime, D. & Ostad, E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv. Exp. Med. Biol. 370, 411-416 (1994).
108. Montesinos, M. C. et al. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 43, 656-663 (2000).
109. Neurath, M. F. et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115, 42-55 (1999).
110. Hayem, G., Domarle, O., Thuong-Guyot, M., Pocidalo, J. J. & Meyer, O. Effects of methotrexate on the oxidative metabolism of cultured rabbit articular chondrocytes. J. Rheumatol. 27, 1117-1120 (2000).
111. Rudwaleit, M. et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor-α, increase of interleukin-10, and predicted by the initial concentration of interleukin-4. Ann. Rheum. Dis. 59, 311-314 (2000).
112. Brody, M., Bohm, I. & Bauer, R. Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin-1β to the interleukin-1 receptor on target cells. Eur. J. Clin. Chem. Clin. Biochem. 31, 667-674 (1993).
113. Segal, R., Mozes, E., Yaron, M. & Tartakovsky, B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum. 32, 370-377 (1989).
114. Segal, R., Yaron, M. & Tartakovsky, B. Rescue of interleukin-1 activity by leucovorin following inhibition by methotrexate in a murine in vitro system. Arthritis Rheum. 33, 1745-1748 (1990).
115. Gregorios, J. B. et al. Morphologic alterations in rat brain following systemic and intraventricular methotrexate injection: light and electron microscopic studies. J. Neuropathol. Exp. Neurol. 48, 33-417 (1989).
116. Hommes, D. et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122, 7-14 (2002).
117. Lali, F. V., Hunt, A. E., Turner, S. J. & Foxwell, B. M. The pyridinyl imidazole inhibitor SF203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J. Biol. Chem. 275, 7395-7402 (2000).
118. Dunn, S. L., Young, E. A., Hall, M. D. & McNulty, S. Activation of astrocyte intracellular signaling pathways by interleukin-1 in rat primary striatal cultures. Glia 37, 31-42 (2002).
119. Jeohn, G. H. et al. Go6976 inhibits LPS-induced microglial TNF-α release by suppressing p38 MAP kinase activation. Neuroscience 114, 689-697 (2002).
120. Jin, S. X., Zhaung, Z. Y., Woolf, C. J. & Ji, R. R. p38 MAPK is activated after a spinal nerve ligation first in spinal cord microglia and then in DRG neurons and contributes to the generation of neuropathic pain. J. Neurosci. 23, 4017-4022 (2003).
121. Kim, S. Y. et al. Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. Neuroreport 13, 2483-2486 (2002).
122. Hamilton, T. A., Ohmori, Y., Tebo, J. M. & Kishore, R. Regulation of macropahge gene expression by pro- and antiinflammatory cytokines. Pathobiology 67, 241-244 (1999).
123. Kontoyiannis, D. et al. Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology. EMBO J. 20, 3760-3770 (2001).
124. Donnelly, R. P., Dickensheets, H. & Finbloom, D. S. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J. Interferon Cytokine Res. 19, 563-573 (1999).
125. Sawada, M., Suzumura, A., Hosoya, H., Marunouchi, T. & Nagatsu, T. Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J. Neurochem. 72, 1466-1471 (1999).
126. Foey, A. D. et al. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-α: role of the p38 and p42/44 mitogen-activated protein kinases. J. Immunol. 160, 920-928 (1998).
127. Huber, T. S. et al. Anticytokine therapies for acute inflammation and the systemic inflammatory response syndrome: IL-10 and ischemia/reperfusion injury. Shock 13, 425-434 (2000).
128. Bachis, A. et al. Interleukin-10 prevents glutamate-mediated cerebellar granule cell death by blocking caspase-3-like activity. J. Neurosci. 21, 3104-3112 (2001).
129. Milligan, E. D. et al. Inflammatory and chronic constriction injury-induced pain states are controlled by spinal delivery of viral and non-viral vectors encoding the antiinflammatory gene, interleukin-10 (IL10). Proc. Soc. Neurosci. 29 (in the press).
130. Kastin, A. J., Alkerstrom, V. & Pan, W. Interleukin-10 as a CNS therapeutic: the obstacle of the blood-brain/blood-spinal cord barrier. Brain Res. Mol. Brain Res. 114, 168-171 (2003).
131. Davidson, B. L. & Breakefield, X. O. Viral vectors for gene delivery to the nervous system. Nature Rev. Neurosci. 4, 353-364 (2003).
132. Xu, Z. L., Mizuguchi, H., Mayumi, T. & Hayakawa, T. Regulated gene expression from adenovirus vectors: a systematic comparison of various inducible systems. Gene 309, 145-151 (2003).
133. Wiesler-Frank, J., Milligan, E. D., Maier, S. F. & Watkins, L. R. in Encyclopedic Reference of Pam (eds Schmidt, R. & Willis, W. D.) (Springer, Berlin, in the press).
134. Volterra, A. & Bezzi, P. in The Tripartite Synapse (eds Volterra, A., Magistretti, P. J. & Hayden, P. G.) 164-182 (Oxford Univ. Press, Oxford, 2002).